The long -acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na?ve to complement inhibitor treatment see

Rondeau, Eric; Scully, Marie; Ariceta, Gema; Barbour, Tom; Cataland, Spero; Heyne, Nils; Miyakawa, Yoshitaka; Ortiz, Stephan; Swenson, Eugene; Vallee, Marc; Yoon, Sung-Soo; Kavanagh, David; Haller, Hermann

dc.contributor.author	Heyne, Nils
dc.date.accessioned	2020-08-31T13:39:01Z
dc.date.available	2020-08-31T13:39:01Z
dc.date.issued	2020
dc.identifier.issn	1523-1755
dc.identifier.uri	http://hdl.handle.net/10900/105988
dc.language.iso	en	de_DE
dc.publisher	Elsevier Science Inc	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.kint.2020.01.035	de_DE
dc.subject.ddc	610	de_DE
dc.title	The long -acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na?ve to complement inhibitor treatment see	de_DE
dc.type	Article	de_DE
utue.quellen.id	20200715072417_00270
utue.publikation.seiten	1287-1296	de_DE
utue.personen.roh	Rondeau, Eric
utue.personen.roh	Scully, Marie
utue.personen.roh	Ariceta, Gema
utue.personen.roh	Barbour, Tom
utue.personen.roh	Cataland, Spero
utue.personen.roh	Heyne, Nils
utue.personen.roh	Miyakawa, Yoshitaka
utue.personen.roh	Ortiz, Stephan
utue.personen.roh	Swenson, Eugene
utue.personen.roh	Vallee, Marc
utue.personen.roh	Yoon, Sung-Soo
utue.personen.roh	Kavanagh, David
utue.personen.roh	Haller, Hermann
dcterms.isPartOf.ZSTitelID	Kidney International	de_DE
dcterms.isPartOf.ZS-Issue	6	de_DE
dcterms.isPartOf.ZS-Volume	97	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE